
Century Therapeutics (IPSC) Stock
Small biotech company developing ready-made immune cell treatments. Here's the price, business snapshot, and what's worth knowing about Century Therapeutics in November 2026.
Century Therapeutics, Inc (ticker IPSC) is an early-stage biotechnology company developing allogeneic cell therapies using induced pluripotent stem cells (iPSCs). The company seeks to create ‘off-the-shelf’ engineered immune cells intended to treat cancer and other diseases, aiming for scalable manufacturing and potential cost advantages versus personalised approaches. With a market capitalisation around $48.8m, Century is a small-cap, typically pre-revenue business where programmes may still be preclinical or in early clinical stages. Investors should note the high scientific, regulatory and financing risks common to cell-therapy developers: clinical trials may fail, manufacturing scale-up can be challenging, and additional capital may be required. The share price can be volatile. This summary is for general educational purposes only and is not personal financial advice; investors should carry out their own research and consider their risk tolerance and investment horizon.
Century Therapeutics (IPSC) Stock Forecast
Analyst price target, next 12 months
$8.51
+425.6% vs today's $1.62
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Century Therapeutics have a consensus 12-month target of $8.51, above the current price of $1.62.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Century Therapeutics' stock, expecting it to rise to $8.51 per share.
Financial Health
Century Therapeutics is performing well with solid cash flow and a positive book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Early-stage biotech
Small market cap and early clinical programmes could offer upside if science succeeds, though outcomes are uncertain and volatility is likely.
iPSC platform potential
iPSC-derived, off-the-shelf cells aim for scalable manufacturing and broader patient reach, but technical and regulatory hurdles remain significant.
Partnerships matter
Collaborations or licences can provide funding and expertise to derisk development, yet deal terms and execution affect prospective value.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.